

## Emplozin SM 25 Tablet

### Empagliflozin 25 mg + Sitagliptin 100 mg + Metformin 1000 mg Tablet

Triple Action Diabetes Control for  
Comprehensive Management of Type 2  
Diabetes

---

#### Description

**Empagliflozin 25 mg + Sitagliptin 100 mg + Metformin 1000 mg** is a **combination tablet** designed for the **effective management of type 2 diabetes mellitus**. This advanced triple therapy integrates three potent agents:

- **Empagliflozin (25 mg):** A Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor
- **Sitagliptin (100 mg):** A Dipeptidyl Peptidase-4 (DPP-4) inhibitor
- **Metformin (1000 mg):** A Biguanide

These medications work together to provide **comprehensive blood sugar control**, improving **insulin sensitivity**, reducing glucose production in the liver, and enhancing glucose excretion through urine. This combination also offers cardiovascular benefits and weight management advantages.

---

#### Mechanism of Action

- **Empagliflozin (25 mg):**  
Empagliflozin inhibits **SGLT2** in the kidneys, preventing glucose reabsorption into the bloodstream and promoting **glucose excretion in urine**. This mechanism not only helps to reduce blood sugar but also supports **weight loss** and offers **blood pressure-lowering** effects, which are beneficial for patients with type 2 diabetes and cardiovascular risk.
- **Sitagliptin (100 mg):**  
Sitagliptin is a **DPP-4 inhibitor** that

increases the levels of **incretin hormones**, which stimulate insulin release from the pancreas and reduce glucagon secretion from the liver. This results in **better blood sugar control**, especially after meals, by enhancing insulin responsiveness and minimizing glucose production by the liver.

- **Metformin (1000 mg):**  
Metformin **reduces hepatic glucose production** and increases insulin sensitivity, allowing the body to utilize glucose more effectively. By enhancing **insulin action**, it helps to regulate blood sugar levels and also supports **weight loss** and improvement of **lipid profiles**.
- 

#### Indications

**Empagliflozin 25 mg + Sitagliptin 100 mg + Metformin 1000 mg** tablet is indicated for:

- **Type 2 Diabetes Mellitus:**
    - To improve **glycemic control** in adults with type 2 diabetes, particularly in patients who do not achieve adequate control with monotherapy or dual therapy.
  - **Cardiovascular Risk Reduction:**
    - **Empagliflozin** has demonstrated a **reduction in cardiovascular events** and death in patients with type 2 diabetes and established cardiovascular disease, making this combination especially beneficial for those at high cardiovascular risk.
  - **Weight Management:**
    - This combination helps promote **modest weight loss** due to the effects of **Empagliflozin** and **Metformin**, which is advantageous for overweight patients with type 2 diabetes.
- 

#### Dosage and Administration

- **Recommended Dose:**
  - The typical dosage is **one tablet (25 mg Empagliflozin + 100 mg Sitagliptin + 1000 mg Metformin)** once daily, preferably with food to minimize gastrointestinal discomfort, especially with **Metformin**.
- **Administration:**
  - Take the tablet whole with water. It is recommended to take the medication at the same time each day to help establish a routine and enhance adherence.

**Note:** Always follow your healthcare provider's instructions for the dosage and schedule. Dosage adjustments may be required based on individual factors such as kidney function and blood sugar control.

---

## Possible Side Effects

### Common Side Effects:

- **Gastrointestinal issues:**
  - **Nausea, diarrhea, and abdominal discomfort** are common, especially when first starting **Metformin**. Taking the tablet with food can help alleviate these symptoms.
- **Urinary tract infections (UTIs):**
  - **Empagliflozin** may increase the risk of **urinary tract infections** due to glucose excretion in the urine.
- **Increased urination and thirst**
  - **Empagliflozin** can cause increased urination and thirst, which can lead to dehydration if not properly managed.
- **Fatigue and respiratory tract infections**

### Serious Side Effects:

- **Hypoglycemia:**
  - While **Empagliflozin** generally does not cause hypoglycemia on its own, **Sitagliptin** combined with **insulin** or other insulin-stimulating medications can increase the risk of low blood sugar. Monitor blood glucose levels regularly,

especially when adding or adjusting other diabetes treatments.

- **Diabetic Ketoacidosis (DKA):**
  - There have been rare reports of **diabetic ketoacidosis (DKA)** with **SGLT2 inhibitors** like **Empagliflozin**. Symptoms may include nausea, vomiting, abdominal pain, and difficulty breathing. Seek immediate medical help if any of these symptoms develop.
- **Kidney problems:**
  - **Empagliflozin** should be used with caution in patients with **renal impairment**, and **Metformin** is contraindicated in patients with **severe kidney disease**. Kidney function should be monitored regularly.
- **Lactic acidosis:**
  - **Metformin** has been associated with a rare but serious condition called **lactic acidosis**, which can be fatal. Symptoms include muscle pain, difficulty breathing, dizziness, and abdominal discomfort. Discontinue Metformin immediately if you experience these symptoms.
- **Pancreatitis:**
  - **Sitagliptin** has been associated with an increased risk of **pancreatitis**. If you experience severe abdominal pain, nausea, or vomiting, discontinue the medication and seek medical attention.
- **Genital infections:**
  - **Empagliflozin** increases the risk of **fungal genital infections**, particularly in women.

---

## Precautions

- **Kidney Function:**
  - **Empagliflozin** should be avoided in patients with **severe renal impairment** (eGFR < 30 mL/min/1.73m<sup>2</sup>). **Metformin** should also be avoided in patients with severe kidney disease. Kidney function should be assessed before starting treatment and monitored regularly during use.
- **Pancreatitis History:**

- Use **Sitagliptin** cautiously in patients with a history of **pancreatitis**. If symptoms of pancreatitis (severe abdominal pain) occur, discontinue the medication and seek medical attention immediately.
- **Diabetic Ketoacidosis (DKA):**
  - Be alert for symptoms of **diabetic ketoacidosis (DKA)**, which include nausea, vomiting, and abdominal pain. Seek urgent medical care if these symptoms develop.
- **Alcohol:**
  - **Metformin** can increase the risk of **lactic acidosis**, particularly with excessive alcohol consumption. Limit alcohol intake to reduce this risk.
- **Pregnancy and Breastfeeding:**
  - **Pregnancy:** This medication is **not recommended during pregnancy** unless the potential benefit outweighs the risk. Consult your doctor for safer alternatives.
  - **Breastfeeding:** The safety of this combination during breastfeeding is not well established. Discuss with your healthcare provider before using this medication while breastfeeding.

---

## Drug Interactions

- **Insulin or Insulin Secretagogues:**
  - **Sitagliptin** may increase the risk of **hypoglycemia** when used with insulin or insulin secretagogues. Monitor blood glucose levels closely when these drugs are combined.
- **Diuretics, ACE Inhibitors, ARBs:**
  - The combination of **Empagliflozin** with these medications may increase the risk of **dehydration** and **low blood pressure**.
- **Lithium:**
  - **Sitagliptin** may increase the levels of **lithium** in the blood, requiring careful monitoring.
- **CYP3A4 Inhibitors:**
  - **Sitagliptin** metabolism may be affected by certain medications, such as **CYP3A4 inhibitors** and **inducers**. Discuss all

other medications with your healthcare provider.

---

## Storage

- Store at **room temperature** (15°C to 30°C).
- Keep the medication in a **dry place**, away from heat, moisture, and direct sunlight.
- Keep out of reach of children.

---

## Disclaimer

**Empagliflozin 25 mg + Sitagliptin 100 mg + Metformin 1000 mg** tablet should be used under the guidance of a healthcare provider. Always follow the prescribed dosage and consult your healthcare provider for any concerns or side effects. For serious side effects or emergencies, seek immediate medical assistance.

---

[Empagliflozin 25 mg + Sitagliptin 100 mg + Metformin 1000 mg Tablet — Comprehensive Triple Therapy for Optimal Diabetes Control and Cardiovascular Protection!](#)

Manufactured in India for:

**Cafeli**<sup>TM</sup>  
L I F E C A R E

Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I,  
Panchkula-134113

TM: Trademark Applied for